0000950170-23-073306.txt : 20231227 0000950170-23-073306.hdr.sgml : 20231227 20231227161511 ACCESSION NUMBER: 0000950170-23-073306 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231222 FILED AS OF DATE: 20231227 DATE AS OF CHANGE: 20231227 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DiPietro Kenneth CENTRAL INDEX KEY: 0001540188 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39311 FILM NUMBER: 231518098 MAIL ADDRESS: STREET 1: C/O BIOGEN IDEC INC. STREET 2: 133 BOSTON POST ROAD CITY: WESTON STATE: MA ZIP: 02493 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cerevel Therapeutics Holdings, Inc. CENTRAL INDEX KEY: 0001805387 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 BUSINESS PHONE: 844-304-2048 MAIL ADDRESS: STREET 1: 222 JACOBS STREET STREET 2: SUITE 200 CITY: CAMBRIDGE STATE: MA ZIP: 02141 FORMER COMPANY: FORMER CONFORMED NAME: ARYA Sciences Acquisition Corp II DATE OF NAME CHANGE: 20200303 4 1 ownership.xml 4 X0508 4 2023-12-22 0001805387 Cerevel Therapeutics Holdings, Inc. CERE 0001540188 DiPietro Kenneth C/O CEREVEL THERAPEUTICS HOLDINGS, INC. 222 JACOBS STREET, SUITE 200 CAMBRIDGE MA 02141 false true false false Chief Human Resources Officer false Common Stock 2023-12-22 4 M false 8000 3.50 A 32663 D Common Stock 2023-12-22 4 S false 8000 41.4510 D 24663 D Stock Option (Right to Buy) 3.50 2023-12-22 4 M false 8000 0.00 D 2029-04-02 Common Stock 8000 302242 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.45 to $41.46. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option is fully vested and exercisable. /s/ Mark Bodenrader, as Attorney-in-Fact 2023-12-27